Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151

Margaret A Fischl, Douglas D. Richman, Charles Flexner, Michael F. Para, Richard Haubrich, Aziz Karim, Patrick Yeramian, Jeanne Holden-Wiltse, Patricia M. Meehan

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

SC-52151, an HIV- 1 protease inhibitor, was developed as an ethanol- based elixir and subsequently as a self-emulsifying drug delivery system (SEDDS) to improve bioavailability. To evaluate formulation and treatment regimen effects, we conducted a four-arm, phase I/II study using the highest previously tested daily dose, 2250 mg. Forty-nine patients received the elixir or SEDDS at a dosage of 750 mg three times daily or 1125 mg twice daily for 14 days. One patient developed hypertriglyceridemia, and one had fever and dyspnea. The SEDDS formulation compared with the elixir resulted in a larger area under the concentration-time curve (AUC, p < 0.001), peak (Cmax, p = 0.041) and trough (Cmin, p = 0.025). Twice-daily administration compared with administration three times daily produced a higher cumulative AUC (p = 0.008). Both SEDDS regimens produced mean plasma concentrations above the 90% inhibitory concentration (IC90) for HIV. A mean decline of 0.03 log10 RNA copies (SEDDS) and an increase of 0.15 log10 (elixir) were observed. Although SC-52151 was well federated and the SEDDS formulation resulted in plasma concentrations above the [C90 for viral replication, no antiviral activity was produced.

Original languageEnglish
Pages (from-to)28-34
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Volume15
Issue number1
StatePublished - May 1 1997

Fingerprint

HIV Protease Inhibitors
Drug Delivery Systems
Pharmacokinetics
Area Under Curve
Hypertriglyceridemia
Dyspnea
Biological Availability
Antiviral Agents
SC 52151
Fever
Ethanol
HIV
RNA

Keywords

  • Antiretroviral therapy
  • HIV-1 protease inhibitor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Virology

Cite this

Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. / Fischl, Margaret A; Richman, Douglas D.; Flexner, Charles; Para, Michael F.; Haubrich, Richard; Karim, Aziz; Yeramian, Patrick; Holden-Wiltse, Jeanne; Meehan, Patricia M.

In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 15, No. 1, 01.05.1997, p. 28-34.

Research output: Contribution to journalArticle

Fischl, MA, Richman, DD, Flexner, C, Para, MF, Haubrich, R, Karim, A, Yeramian, P, Holden-Wiltse, J & Meehan, PM 1997, 'Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151', Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 15, no. 1, pp. 28-34.
Fischl, Margaret A ; Richman, Douglas D. ; Flexner, Charles ; Para, Michael F. ; Haubrich, Richard ; Karim, Aziz ; Yeramian, Patrick ; Holden-Wiltse, Jeanne ; Meehan, Patricia M. / Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. In: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1997 ; Vol. 15, No. 1. pp. 28-34.
@article{e4032018292d4cb3b98dad1db5865c11,
title = "Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151",
abstract = "SC-52151, an HIV- 1 protease inhibitor, was developed as an ethanol- based elixir and subsequently as a self-emulsifying drug delivery system (SEDDS) to improve bioavailability. To evaluate formulation and treatment regimen effects, we conducted a four-arm, phase I/II study using the highest previously tested daily dose, 2250 mg. Forty-nine patients received the elixir or SEDDS at a dosage of 750 mg three times daily or 1125 mg twice daily for 14 days. One patient developed hypertriglyceridemia, and one had fever and dyspnea. The SEDDS formulation compared with the elixir resulted in a larger area under the concentration-time curve (AUC, p < 0.001), peak (Cmax, p = 0.041) and trough (Cmin, p = 0.025). Twice-daily administration compared with administration three times daily produced a higher cumulative AUC (p = 0.008). Both SEDDS regimens produced mean plasma concentrations above the 90{\%} inhibitory concentration (IC90) for HIV. A mean decline of 0.03 log10 RNA copies (SEDDS) and an increase of 0.15 log10 (elixir) were observed. Although SC-52151 was well federated and the SEDDS formulation resulted in plasma concentrations above the [C90 for viral replication, no antiviral activity was produced.",
keywords = "Antiretroviral therapy, HIV-1 protease inhibitor",
author = "Fischl, {Margaret A} and Richman, {Douglas D.} and Charles Flexner and Para, {Michael F.} and Richard Haubrich and Aziz Karim and Patrick Yeramian and Jeanne Holden-Wiltse and Meehan, {Patricia M.}",
year = "1997",
month = "5",
day = "1",
language = "English",
volume = "15",
pages = "28--34",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "1",

}

TY - JOUR

T1 - Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151

AU - Fischl, Margaret A

AU - Richman, Douglas D.

AU - Flexner, Charles

AU - Para, Michael F.

AU - Haubrich, Richard

AU - Karim, Aziz

AU - Yeramian, Patrick

AU - Holden-Wiltse, Jeanne

AU - Meehan, Patricia M.

PY - 1997/5/1

Y1 - 1997/5/1

N2 - SC-52151, an HIV- 1 protease inhibitor, was developed as an ethanol- based elixir and subsequently as a self-emulsifying drug delivery system (SEDDS) to improve bioavailability. To evaluate formulation and treatment regimen effects, we conducted a four-arm, phase I/II study using the highest previously tested daily dose, 2250 mg. Forty-nine patients received the elixir or SEDDS at a dosage of 750 mg three times daily or 1125 mg twice daily for 14 days. One patient developed hypertriglyceridemia, and one had fever and dyspnea. The SEDDS formulation compared with the elixir resulted in a larger area under the concentration-time curve (AUC, p < 0.001), peak (Cmax, p = 0.041) and trough (Cmin, p = 0.025). Twice-daily administration compared with administration three times daily produced a higher cumulative AUC (p = 0.008). Both SEDDS regimens produced mean plasma concentrations above the 90% inhibitory concentration (IC90) for HIV. A mean decline of 0.03 log10 RNA copies (SEDDS) and an increase of 0.15 log10 (elixir) were observed. Although SC-52151 was well federated and the SEDDS formulation resulted in plasma concentrations above the [C90 for viral replication, no antiviral activity was produced.

AB - SC-52151, an HIV- 1 protease inhibitor, was developed as an ethanol- based elixir and subsequently as a self-emulsifying drug delivery system (SEDDS) to improve bioavailability. To evaluate formulation and treatment regimen effects, we conducted a four-arm, phase I/II study using the highest previously tested daily dose, 2250 mg. Forty-nine patients received the elixir or SEDDS at a dosage of 750 mg three times daily or 1125 mg twice daily for 14 days. One patient developed hypertriglyceridemia, and one had fever and dyspnea. The SEDDS formulation compared with the elixir resulted in a larger area under the concentration-time curve (AUC, p < 0.001), peak (Cmax, p = 0.041) and trough (Cmin, p = 0.025). Twice-daily administration compared with administration three times daily produced a higher cumulative AUC (p = 0.008). Both SEDDS regimens produced mean plasma concentrations above the 90% inhibitory concentration (IC90) for HIV. A mean decline of 0.03 log10 RNA copies (SEDDS) and an increase of 0.15 log10 (elixir) were observed. Although SC-52151 was well federated and the SEDDS formulation resulted in plasma concentrations above the [C90 for viral replication, no antiviral activity was produced.

KW - Antiretroviral therapy

KW - HIV-1 protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0030769322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030769322&partnerID=8YFLogxK

M3 - Article

C2 - 9215651

AN - SCOPUS:0030769322

VL - 15

SP - 28

EP - 34

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 1

ER -